ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past ...
SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...
It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...
1d
Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story?
AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic ...
2don MSN
AbbVie in advanced talks to buy cancer drugmaker Revolution Medicines, shares jump nearly 30%
AbbVie is in advanced talks to buy Revolution Medicines, a cancer drug company. The news pushed Revolution Medicines shares ...
Jan 7 (Reuters) - AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines, the Wall Street ...
AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines, the Wall Street Journal reported on Wednesday, ...
Samsung Bioepis reviews Organon acquisition to boost direct biosimilar sales Samsung Bioepis explores direct sales expansion ...
AbbVie Inc. (NYSE: ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s ...
Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...
A federal judge has allowed South Dakota’s new 340B drug‑discount law to remain in effect while a legal challenge from pharmaceutical giant AbbVie moves forward.
John Hult, South Dakota Searchlight A South Dakota law that prevents drug companies from restricting federal drug discounts for hospitals and other providers will remain in effect for now, a judge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback